FENC
Fennec Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
3.85 / 10
Netural
Analyst sentiment is lukewarm: only one active analyst exists, issuing a single Buy rating with a historical win rate of 0.0%—hardly compelling. Fund-flow metrics register a solid 7.7/10, yet all size brackets (block, small, medium, large, extra-large) display negative trends, suggesting accumulation without conviction. The mismatch between positive flow and negative directional signals implies that any inflows could be short-term or hedging in nature. Investors should await either a shift in analyst consensus or a sustained positive flow before viewing FENC as an attractive proposition.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-09
InstitutionPiper Sandler
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for FENC?
- FENC holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.85/10 (Netural).
